246 related articles for article (PubMed ID: 12501133)
1. Intracellular concentration of protease inhibitors in HIV-1-infected patients: correlation with MDR-1 gene expression and low dose of ritonavir.
Chaillou S; Durant J; Garraffo R; Georgenthum E; Roptin C; Clevenbergh P; Dunais B; Mondain V; Roger PM; Dellamonica P
HIV Clin Trials; 2002; 3(6):493-501. PubMed ID: 12501133
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of a twice-daily antiretroviral regimen containing 100 mg ritonavir/400 mg indinavir in HIV-infected patients.
Ghosn J; Lamotte C; Ait-Mohand H; Wirden M; Agher R; Schneider L; Bricaire F; Duvivier C; Calvez V; Peytavin G; Katlama C
AIDS; 2003 Jan; 17(2):209-14. PubMed ID: 12545081
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic drug monitoring of saquinavir in patients during protease inhibitor therapy with saquinavir alone or in combination with ritonavir or nelfinavir.
Langmann P; Zilly M; Weissbrich B; Schlör C; Väth T; Richter E; Klinker H
Eur J Med Res; 2000 Feb; 5(2):59-62. PubMed ID: 10720564
[TBL] [Abstract][Full Text] [Related]
4. The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy.
Cardiello P; Srasuebkul P; Hassink E; Mahanontharit A; Samor T; Ruxrungtham K; Lange J; Cooper D; Phanuphak P
HIV Med; 2005 Mar; 6(2):122-8. PubMed ID: 15807718
[TBL] [Abstract][Full Text] [Related]
5. Once-daily dosing of saquinavir soft-gel capsules and ritonavir combination in HIV-1-infected patients (IMEA015 study).
Lamotte C; Landman R; Peytavin G; Mentre F; Gerbe J; Brun-Vezinet F; Boue F; Spiridon G; Valantin MA; Michelet C; Farinotti R; Yeni P
Antivir Ther; 2004 Apr; 9(2):247-56. PubMed ID: 15134187
[TBL] [Abstract][Full Text] [Related]
6. Inhibitory quotient as a prognostic factor of response to a salvage antiretroviral therapy containing ritonavir-boosted saquinavir. The CIVSA Study.
Mallolas J; Blanco J; Labarga P; Vergara A; Ocampo A; Sarasa M; Arnedo M; López-Púa Y; García J; Juega J; Guelar A; Terrón A; Dalmau D; García I; Zárraga M; Martínez E; Carné X; Pumarola T; Escayola R; Gatell J
HIV Med; 2007 May; 8(4):226-33. PubMed ID: 17461850
[TBL] [Abstract][Full Text] [Related]
7. Intracellular accumulation of human immunodeficiency virus protease inhibitors.
Khoo SH; Hoggard PG; Williams I; Meaden ER; Newton P; Wilkins EG; Smith A; Tjia JF; Lloyd J; Jones K; Beeching N; Carey P; Peters B; Back DJ
Antimicrob Agents Chemother; 2002 Oct; 46(10):3228-35. PubMed ID: 12234849
[TBL] [Abstract][Full Text] [Related]
8. SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients.
Gathe JC; Ive P; Wood R; Schürmann D; Bellos NC; DeJesus E; Gladysz A; Garris C; Yeo J
AIDS; 2004 Jul; 18(11):1529-37. PubMed ID: 15238771
[TBL] [Abstract][Full Text] [Related]
9. Differences in the detection of three HIV-1 protease inhibitors in non-blood compartments: clinical correlations.
Lafeuillade A; Solas C; Halfon P; Chadapaud S; Hittinger G; Lacarelle B
HIV Clin Trials; 2002; 3(1):27-35. PubMed ID: 11819183
[TBL] [Abstract][Full Text] [Related]
10. Performance of six different ritonavir-boosted protease inhibitor-based regimens in heavily antiretroviral-experienced HIV-infected patients.
de Mendoza C; Valer L; Ribera E; Barreiro P; Martín-Carbonero L; Ramirez G; Soriano V
HIV Clin Trials; 2006; 7(4):163-71. PubMed ID: 17065028
[TBL] [Abstract][Full Text] [Related]
11. Simplifying protease inhibitor therapy with once-daily dosing of saquinavir soft-gelatin capsules/ritonavir (1600/100 mg): HIVNAT 001.3 study.
Cardiello PG; van Heeswijk RP; Hassink EA; Srasuebkul P; Mahanontharit A; Samor TM; Worarien W; Beijnen JH; Hoetelmans RM; Ruxrungtham K; Cooper DA; Lange JM; Phanuphak P
J Acquir Immune Defic Syndr; 2002 Apr; 29(5):464-70. PubMed ID: 11981362
[TBL] [Abstract][Full Text] [Related]
12. Twice-daily amprenavir 1200 mg versus amprenavir 600 mg/ritonavir 100 mg, in combination with at least 2 other antiretroviral drugs, in HIV-1-infected patients.
Nadler JP; Gathe JC; Pollard RB; Richmond GJ; Liao Q; Griffith S; Lancaster CT; Hernandez JE; Pappa KA;
BMC Infect Dis; 2003 Jun; 3():10. PubMed ID: 12795812
[TBL] [Abstract][Full Text] [Related]
13. Regimen-dependent variations in adherence to therapy and virological suppression in patients initiating protease inhibitor-based highly active antiretroviral therapy.
Moore DM; Hogg RS; Yip B; Wood E; Harris M; Montaner JS
HIV Med; 2006 Jul; 7(5):311-6. PubMed ID: 16945076
[TBL] [Abstract][Full Text] [Related]
14. Cerebrospinal fluid HIV-1 RNA during treatment with ritonavir/saquinavir or ritonavir/saquinavir/stavudine.
Gisolf EH; Enting RH; Jurriaans S; de Wolf F; van der Ende ME; Hoetelmans RM; Portegies P; Danner SA
AIDS; 2000 Jul; 14(11):1583-9. PubMed ID: 10983645
[TBL] [Abstract][Full Text] [Related]
15. Safety, tolerability, and antiretroviral effects of ritonavir-nelfinavir combination therapy administered for 48 weeks.
Raines CP; Flexner C; Sun E; Heath-Chiozzi M; Lewis RH; Fields C; Deetz C; Apuzzo L; Eshleman SH; Jackson JB; Gallant JE
J Acquir Immune Defic Syndr; 2000 Dec; 25(4):322-8. PubMed ID: 11114832
[TBL] [Abstract][Full Text] [Related]
16. Hepatic and intestinal contributions to pharmacokinetic interaction of indinavir with amprenavir, nelfinavir and saquinavir in rats.
Gao W; Kishida T; Kageyama M; Kimura K; Yoshikawa Y; Shibata N; Takada K
Antivir Chem Chemother; 2002 Jan; 13(1):17-26. PubMed ID: 12180646
[TBL] [Abstract][Full Text] [Related]
17. A clinical study of the combination of 100 mg ritonavir plus 800 mg indinavir as salvage therapy: influence of increased plasma drug levels in the rate of response.
Casado JL; Moreno A; Sabido R; Martí-Belda P; Antela A; Dronda F; Perez-Elías MJ; Moreno S
HIV Clin Trials; 2000; 1(1):13-9. PubMed ID: 11590485
[TBL] [Abstract][Full Text] [Related]
18. Indinavir/ritonavir-based therapy in HIV-1-infected antiretroviral therapy-naive patients: comparison of 800/100 mg and 400/100 mg twice daily.
Konopnicki D; De Wit S; Poll B; Crommentuyn K; Huitema A; Clumeck N
HIV Med; 2005 Jan; 6(1):1-6. PubMed ID: 15670245
[TBL] [Abstract][Full Text] [Related]
19. Efficacy, tolerance, and pharmacokinetics of the combination of stavudine, nevirapine, nelfinavir, and saquinavir as salvage regimen after ritonavir or indinavir failure.
Casado JL; Dronda F; Hertogs K; Sabido R; Antela A; Martí-Belda P; Dehertogh P; Moreno S;
AIDS Res Hum Retroviruses; 2001 Jan; 17(2):93-8. PubMed ID: 11177388
[TBL] [Abstract][Full Text] [Related]
20. Comparison of two indinavir/ritonavir regimens in the treatment of HIV-infected individuals.
Acosta EP; Wu H; Hammer SM; Yu S; Kuritzkes DR; Walawander A; Eron JJ; Fichtenbaum CJ; Pettinelli C; Neath D; Ferguson E; Saah AJ; Gerber JG;
J Acquir Immune Defic Syndr; 2004 Nov; 37(3):1358-66. PubMed ID: 15483465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
